Dual-action drug candidate seeks to regulate metabolic profile and reduce inflammation

by

Pharmacology
–

Metabolic syndrome

They are investigating a pan-PPAR agonist in metabolic syndrome that, due to its different mechanisms, can reduce the number of drugs consumed and adherence problems.

Incliva researchers Carlos Villarroel-Vicente, Patrice Marques, Laura Piqueras, María Jesús Sanz, Nuria Cabedo, Laura Vila, Ainhoa ​​García and Álvaro Bernabeu. Photo: INCLIVA

Photo of author

Alexandra Hartman Editor-in-Chief

Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

La Liga returns to the Santiago Bernabéu

for Volodymyr Zelensky, the Russian presidency of the UN proves “the bankruptcy” of the institution

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.